Reservoir Neuroscience is developing a scaffold of small molecule inhibitors that can cross the blood brain barrier (BBB), inhibit TGFβ signaling, and relieve chronic inflammatory load in the aging brain. The product aims to ultimately restore BBB integrity and neural function. These types of drugs are claimed to revitalize the aging brain and restore cognitive function to a “youthful” level in older animals.
Co-Founder and CEO Aaron Friedman earned his Ph.D. in 2018 from the department of Integrative Biology at University of California, Berkeley working on “Cumulative and Persistent Changes in the Brain in Response to Stress and Aging.”
Co-Founder and CEO